(MENAFN- GlobeNewsWire - Nasdaq) itemprop="articleBody">
Correction: Resolutions of the Annual General Meeting
This release is a correction to BBS-Bioactive Bone Substitutes´ Resolutions of the Annual General Meeting company release issued on the 5th April 2019 at 4:00 PM (UTC).
The correction refers to the decision to elect Ilkka Kangasniemi as a new Board member and not as a re-elected Board member.
The sentence: 'The AGM decided that the number of Board members will be six (6). Until the end of next AGM, was re-elected Jarmo Halonen, Pekka Jalovaara, Auvo Kaikkonen, Tomi Numminen, Hannu Säynäjäkangas and Ilkka Kangasniemi.' is incorrect and should instead read 'The AGM decided that the number of Board members will be six (6). Until the end of next AGM, was re-elected Jarmo Halonen, Pekka Jalovaara, Auvo Kaikkonen, Tomi Numminen, Hannu Säynäjäkangas. Ilkka Kangasniemi was elected as a new Board member.'
The correct Resolutions of the Annual General Meeting
BBS-Bioactive Bone Substitutes Oyj's Annual General Meeting (AGM) was held today, on Friday 5th April 2019 from 2:00 pm in Oulu. The AGM confirmed the financial statements for the financial year 2018, discharged the Board of Directors and the CEO from liability. The AGM decided that the company will not pay dividends for the financial year 2018.
The board of directors and the auditor
The AGM decided that the number of Board members will be six (6). Until the end of next AGM, was re-elected Jarmo Halonen, Pekka Jalovaara, Auvo Kaikkonen, Tomi Numminen, Hannu Säynäjäkangas. Ilkka Kangasniemi was elected as a new Board member. The AGM decided that the chairman of the board be paid EUR 750 per meeting and EUR 500 per meeting for other members. No compensation will be paid for e-mail meetings. In addition, the travel expenses of the members of the board are reimbursed according to the company's travel rule.
As the company's auditor was re-elected Ernst & Young Oy, which announced that KHT Juhani Rönkkö will act as the company's principal auditor. The auditor is paid a fee according to a reasonable invoice approved by the company.
Board authorizations
The AGM decided to authorize the board to decide on the issuance of a share issue that does not exclude the right of the board to decide on a directed share issue. The share issue may be exercised to increase the share capital by issuing a share issue or convertible bonds in one or more installments under the following rules:
The board is authorized to decide to increase the share capital by issuing a share issue or issuing convertible bonds in one or more installments. A new subscription or, alternatively convertible bonds entitles to subscribe for up to (a million and five hundred thousand) 1.500.000 new shares. The company currently has 5.090.520 shares. It was decided to terminate the old authorizations.
The authorization includes the right to deviate from the shareholder's pre-emptitive right to subscribe for new shares or convertible bonds as well as the right to decide on the share subscription price, subscription rights and the subscription terms. The subscription price of the share is recognized in the invested unrestricted equity fund. The authorization may be exercised in the deviation from the shareholder's pre-emptitive subscription rights, if there is a weighty financial reason for the company, such as extending the company's shareholder base or other arrangements for the company's business development or capital incentive scheme or capital maintenance. Under the authorization shares may be offered to those belonging to related party in the deviation from the shareholder's pre-emptitive rights, but not for the benefit of related persons. The board is entitled to decide that the shares can be subscribed for against a contribution, using the right of set-off or otherwise on specific terms. Possible options are used at the discretion of the board.
The authorization is valid until the next AGM but up to a maximum of 30th June 2020.
The minutes of the AGM are available on the Company's website www.bbs-artebone.fi, at no later than 12th April 2019.
In Oulu, April 5th 2019
BBS-Bioactive Bone Substitutes Oyj
More Information:
CEO Pekka Jalovaara
Phone: 050 552 9275, e-mail: pekka.jalovaara(at)bbs-artebone.fi
CFO Hannu Säynäjäkangas
Phone: 040 502 1092, e-mail: hannu.saynajakangas(at)bbs-artebone.fi
About BBS – Bioactive Bone Substitutes Plc
BBS-Bioactive Bone Substitutes Plc is a leading orthobiologic biotech company with origins in Finland. The company's technology, Artebone®, is a next generation bone substitute that targets treatment of bone defects and healing problems in extremities such as hands and ankles, scapula and pelvis. Its superior properties stem from the natural growth factors extracted from reindeer bone combined with scaffold-providing TCP (tricalciumphosphate) granules and has the potential of transforming orthopedic surgery. The first product, Artebone® Paste, is ready and the application process for the CE-marking enabling commercialization is in progress. BBS' Certified Adviser at Nasdaq First North Sweden and Finland is Stockholm Certified Advisers AB, +46 70 5516 729, . More information: www.bbs-artebone.fi .
MENAFN1305201900703653ID1098516345
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.